case study

Gap Analysis for Electronic Records

RCA was contracted to perform a gap assessment of eight quality software systems and 29 laboratory software systems. After reviewing remediation plans, the FDA chose not to make a regulatory observation.

About RCA
Regulatory Compliance Associates® Inc. (RCA) provides worldwide services to the pharmaceutical, biologic, sterile compounding, biotechnology, and medical device industries for resolution of compliance and regulatory challenges.

Please complete the form to access the case study.

*=Required

Gap Analysis for Electronic Records

Background

In preparing for an upcoming audit by the FDA, a pharmaceutical-grade bulk chemical manufacturer required a gap analysis to determine compliance of quality and laboratory software to requirements for Electronic Records (21 CFR Part 11).

After reviewing remediation plans, the FDA chose not to make a regulatory observation.

 

Challenge

RCA was contracted to perform a gap analysis of eight quality software systems and twenty-nine lab software systems.

 

Approach

Regulatory Compliance Associates® Inc. developed an assessment strategy that involved client interviews for each of the software systems to determine compliance with specific requirements of Part 11. Then a risk assessment was performed to determine highest risk software systems based on compliance with Part 11. Finally the software systems were prioritized based on the risk analysis. This prioritization was used to develop a remediation plan to bring all software into compliance.

 

Result

gap analysisThe results of the gap assessment, risk analysis, and prioritization were presented to the client. Within a month, the FDA visited the client and reviewed the assessment and remediation plans. The FDA determined that the client had adequately demonstrated that they were in the process of complying with Part 11, and did not make a regulatory observation.

 

 

About RCA

life science consultantsRegulatory Compliance Associates® (RCA) provides worldwide services to the following industries for resolution of compliance and regulatory challenges:

 

 

We understand the complexities of running a life science business and possess areas of expertise that include every facet of R&D, operations, regulatory affairs, quality, and manufacturing. We are used to working on the front lines and thriving in the scrutiny of FDA-and globally-regulated companies. As your partners, we can negotiate the potential minefield of regulatory compliance and private equity due diligence with insight, hindsight, and the clear advantage of our unique expertise and experience.

 

 

To begin the RCA® scoping process today, please enter your information in the blue form below and click the submit button at the bottom of the webpage. 

References

  1. FDA Code of Federal Regulations, Title 21, Part 11, “Electronic Records; Electronic Signatures.” Final Rule, March 1997.
  2. U.S. Department of Health and Human Services, Food and Drug Administration, “Guidance for Industry: Part 11, Electronic Records; Electronic Signatures—Scope and Application,” August 2003.
  3. International Society for Pharmaceutical Engineering (ISPE), Good Automated Manufacturing Practices 4 (GAMP4), December 2001.
  4. International Society for Pharmaceutical Engineering (ISPE), Good Automated Manufacturing Practices 5 (GAMP5), April 2008.

Background

In preparing for an upcoming audit by the FDA, a pharmaceutical-grade bulk chemical manufacturer required a gap analysis to determine compliance of quality and laboratory software to requirements for Electronic Records (21 CFR Part 11).

After reviewing remediation plans, the FDA chose not to make a regulatory observation.

 

Challenge

RCA was contracted to perform a gap analysis of eight quality software systems and twenty-nine lab software systems.

 

Approach

Regulatory Compliance Associates® Inc. developed an assessment strategy that involved client interviews for each of the software systems to determine compliance with specific requirements of Part 11. Then a risk assessment was performed to determine highest risk software systems based on compliance with Part 11. Finally the software systems were prioritized based on the risk analysis. This prioritization was used to develop a remediation plan to bring all software into compliance.

 

Result

gap analysisThe results of the gap assessment, risk analysis, and prioritization were presented to the client. Within a month, the FDA visited the client and reviewed the assessment and remediation plans. The FDA determined that the client had adequately demonstrated that they were in the process of complying with Part 11, and did not make a regulatory observation.

 

 

About RCA

life science consultantsRegulatory Compliance Associates® (RCA) provides worldwide services to the following industries for resolution of compliance and regulatory challenges:

 

 

We understand the complexities of running a life science business and possess areas of expertise that include every facet of R&D, operations, regulatory affairs, quality, and manufacturing. We are used to working on the front lines and thriving in the scrutiny of FDA-and globally-regulated companies. As your partners, we can negotiate the potential minefield of regulatory compliance and private equity due diligence with insight, hindsight, and the clear advantage of our unique expertise and experience.

 

 

To begin the RCA® scoping process today, please enter your information in the blue form below and click the submit button at the bottom of the webpage. 

Our website uses cookies to give you the best possible experience.

By continuing to use this site, you agree to the use of cookies.
Continue